2 results
Approved WMOCompleted
Primary:• To evaluate the ability of relugolix to achieve and maintain serum testosterone suppression to castrate levels (<= 50 ng/dL [1.7 nmol/L]) in men with androgen-sensitive advanced prostate cancer.Secondary:• To evaluate the time…
Approved WMOCompleted
To validate the use of the Livv Mobiel ECG as a reliable office/bedside screening tool in primary care practice